Menopause Drug Pipeline 2026: What's Approved, What's in Trials, and What's Stuck

Q: What is the newest FDA-approved menopause drug?

Lynkuet (elinzanetant) is the newest FDA-approved prescription drug specifically for moderate-to-severe vasomotor symptoms due to menopause, approved October 24, 2025. It is a non-hormonal NK1/NK3 antagonist. Its label was revised in August 2026 to add a seizure warning.

Q: How many non-hormonal drugs are FDA-approved for menopausal hot flashes?

Three branded prescription products are FDA-approved specifically for moderate-to-severe vasomotor symptoms associated with menopause: Brisdelle, Veozah, and Lynkuet. Veozah and Lynkuet are the two newer neurokinin-targeting drugs.

Q: What's the difference between Brisdelle, Veozah, and Lynkuet?

Brisdelle is low-dose paroxetine and has an important tamoxifen interaction. Veozah blocks NK3, carries a boxed hepatotoxicity warning, and requires six liver panels through month nine. Lynkuet blocks NK1 and NK3, is taken at bedtime, requires baseline and month-three liver tests, and carries warnings for daytime impairment, pregnancy risk, photosensitivity, and seizure risk.

Q: When will the next new menopause drug be approved?

No investigational candidate in this tracker has a confirmed U.S. marketing application or review date as of September 2, 2026. Today’s Phase 2 programs would still need later-stage evidence, an application, and FDA review. “2030 or later” is an earliest-case editorial estimate, not company guidance.

Q: Why does Veozah have a boxed warning and Lynkuet does not?

FDA added Veozah’s boxed warning after a postmarketing report of serious liver injury and strengthened its testing schedule. Lynkuet does not have a boxed warning, but its label still requires liver testing and now includes a seizure warning added in August 2026.

Q: Do Veozah and Lynkuet require blood tests?

Yes. Both require baseline liver testing. Veozah requires repeat testing monthly for the first three months and again at months six and nine. Lynkuet requires repeat testing at month three. Neither should be started when specified liver enzymes or bilirubin are at least twice the upper limit of normal.

Q: How much do Veozah and Lynkuet cost without insurance?

Pharmacy cash prices vary. Lynkuet’s official affordability program lists $625 for a 30-day supply for eligible people without insurance or without coverage. Veozah does not publish one universal cash price on its savings page. Commercially insured patients may qualify for manufacturer savings, subject to the live terms.

Q: Can a woman taking tamoxifen use a non-hormonal menopause drug?

That is not a one-drug-fits-all decision. Brisdelle’s label warns that paroxetine can reduce tamoxifen effectiveness. Elinzanetant was studied in OASIS-4 among women taking tamoxifen or aromatase inhibitors, but the U.S. label is not a breast-cancer-specific indication. The oncology team should be part of the decision.

Q: Is Fylrevy available in the United States?

Not as an FDA-approved product. Fylrevy received European Union marketing authorization in March 2026. We found no public confirmation of a U.S. submission, accepted application, review, or launch by September 2, 2026.

Q: Is there a pill that can delay menopause?

No drug is FDA-approved to delay natural menopause or ovarian aging. Rapamycin is being studied in a small investigator-led trial, but it is not approved for this purpose and should not be self-prescribed for ovarian aging.

The HRT Index Editorial TeamIndependent women's health research

Last reviewed:September 2, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: September 2, 2026 · Last verified: September 2, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Before you wait for a new menopause treatment

Separate treatments that are available now from investigational drugs, stalled programs, and the care route that fits your symptoms.

Use Find My HRT Path

The menopause drug pipeline in 2026 is real, but it is narrower than the headlines make it sound. The newest U.S. arrivals are fezolinetant (Veozah, 2023) and elinzanetant (Lynkuet, 2025), both non-hormonal neurokinin drugs for moderate-to-severe hot flashes. Brisdelle, a low-dose paroxetine product, was already FDA-approved for the same symptom category.

Beyond those three U.S.-approved drugs, the named programs we could verify are approved only outside the United States, still investigational, funding-dependent, stale, or discontinued. No active candidate in this tracker has a publicly confirmed U.S. marketing application. Waiting has no date.

Here is the part almost nobody tells you: the “new drug” most women are waiting for is usually already at the pharmacy. And one of the most talked-about menopause drugs of 2026 was approved in Europe in March while its U.S. path stayed quiet. We will show you exactly where each one stands, with dates.

Best for you if: you want to know which menopause drugs are approved, which are still being tested, and which quietly stalled before you decide whether to keep waiting.

Not for you if: you need a personal prescription decision, you have new or urgent symptoms, or you are hoping a positive Phase 2 headline means a drug is safe, effective, and close. It does not.

The key number: five non-hormonal candidates are active enough to track in September 2026. Four had a dated 2026 result, publication, or regulatory event; asimadoline remains a registered Phase 2a program without published efficacy results. Not fifty. Five.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

Where does every menopause drug stand right now?

Three non-hormonal prescription drugs are FDA-approved for menopausal hot flashes, one hormone drug is approved in Europe but not the United States, five investigational non-hormonal candidates remain active enough to track, and the rest are stalled, funding-dependent, or discontinued. The status—not the press-release adjective—is what matters.

Status	What it means	Drugs or programs in it — verified September 2, 2026
FDA-approved in the U.S.	Available by prescription for the approved indication	Brisdelle (paroxetine mesylate 7.5 mg); Veozah (fezolinetant); Lynkuet (elinzanetant)
Approved in Europe, not the U.S.	Authorized in the EU and launched in selected pilot markets, but not U.S. access	Fylrevy (estetrol; developed as Donesta)
Active or recent human development	A registered human study plus a current program, or a verified 2026 result, publication, or regulatory step	ABCL635; asimadoline; cendifensine; refisolone; GS1-144
Registered or completed; next step unverified	A study exists or finished, but no later-stage move was confirmed	HS-10384; Q-122
Funding-dependent	The company says more capital or non-dilutive funding is needed	DARE-HRT1; DARE-VVA1
Discontinued	Development stopped	MLE-301; SJX-653

Here is our honest limitation, up front: this pipeline is lopsided. Almost every active program is aimed at hot flashes and night sweats. If your worst symptom is joint pain, brain fog, low libido, or vaginal dryness, there is very little being built for that symptom specifically—and we are not going to pad the list to pretend otherwise.

Why that still makes this page useful: a padded “100+ drugs in development” report tells you nothing. A short, dated, honestly labeled list tells you whether waiting is a plan or a stall. That is the whole job of this page.

The right online HRT provider isn’t the same for every woman—it depends on your symptoms, your age and whether you have a uterus, your medication route preference, your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer cannot resolve those variables, when the answer is “it depends on your situation” → use The HRT Index's Find My HRT Path tool—and use its safety flag for when online care isn't the right starting point—before your first consult.

What's actually in the menopause drug pipeline in 2026?

The menopause drug pipeline in 2026 contains five active or recently active investigational non-hormonal programs for hot flashes, two older programs without a verified next step, two capital-dependent hormone programs, and two discontinued NK3 programs. No investigational drug listed here has a confirmed U.S. approval application or launch date.

A pipeline is not a delivery schedule. It is a queue of maybes. Phase 1 generally asks how a drug behaves in people and whether early safety supports more testing. Phase 2 starts testing dose and efficacy. Phase 3 supplies the larger, longer evidence usually needed for an application. Then the FDA still has to review the full package.

We counted a program as active only when we could trace a human study and a current development signal: a live registry record, a dated result, a peer-reviewed publication, a regulatory step, or a company filing. “A company still lists it on its website” is not enough. Neither is “a market-research report mentioned it.”

The September 2026 menopause drug pipeline tracker

This tracker separates access from activity. “FDA-approved” means a clinician can prescribe the finished U.S. product for its labeled use. “Trial only” means investigational. “No verified next step” means exactly that—not failed, not approved, and not secretly close. Each milestone is dated so stale pipeline coverage is easier to spot.

Drug or program	Type and target	Developer	Current status	Latest verified milestone	U.S. access
Brisdelle (paroxetine mesylate 7.5 mg)	SSRI; non-hormonal	Legacy Pharma	FDA-approved	Approved for moderate-to-severe vasomotor symptoms associated with menopause; current label checked September 2, 2026	Prescription
Fezolinetant (Veozah)	Oral NK3 antagonist; non-hormonal	Astellas	FDA-approved	Approved May 12, 2023; boxed warning for hepatotoxicity added in December 2024	Prescription
Elinzanetant (Lynkuet)	Oral NK1/NK3 antagonist; non-hormonal	Bayer	FDA-approved	Approved October 24, 2025; label revised August 2026 to add a seizure warning	Prescription
Estetrol (Fylrevy; developed as Donesta)	Oral estrogen; hormonal	Gedeon Richter	EU-approved; not FDA-approved	European marketing authorization dated March 26, 2026; Richter reported launch in selected pilot markets by August 7, 2026; no public U.S. submission or acceptance confirmed	Not an FDA-approved U.S. product
ABCL635	Long-acting subcutaneous NK3-blocking antibody; non-hormonal	AbCellera	Phase 1/2; company-reported positive Phase 2 portion	August 10, 2026: one 600 mg injection produced an 83% mean frequency reduction versus 33% with placebo at week 4 in 92 women	Investigational; trial only
Asimadoline (TP0052)	Peripherally acting kappa-opioid receptor agonist; non-hormonal	Tioga Pharmaceuticals	Phase 2a registered; no efficacy result	Randomized, double-blind, placebo-controlled protocol with eight blinded treatment weeks and four open-label weeks; registry record should be checked live before contacting a site	Investigational
Cendifensine (NOE-115)	Triple monoamine reuptake inhibitor; non-hormonal	Noema Pharma	Phase 2a complete; open-label, no placebo	Sponsor announced 2025 results and presented them in 2026; a Phase 2b was discussed but no registered Phase 2b was verified	Not currently available
Refisolone (PH80)	Intranasal pherine; company describes non-systemic action; non-hormonal	Vistagen	Phase 2 development	April 22, 2026: FDA sent a “Study May Proceed” letter under the IND, allowing further U.S. study—not approving the drug	Investigational
GS1-144	Oral NK3 antagonist; non-hormonal	GenSci	Phase 2 complete in China	Peer-reviewed 2026 report of a randomized, double-blind, placebo-controlled 12-week study in 276 women; no U.S. program verified	No U.S. access
HS-10384	Mechanism not clearly disclosed in the public record reviewed	Hansoh BioMedical	Phase 2 record; status stale or unclear	Registry target of 195 participants; no result or current development milestone verified	No
Q-122	Non-hormonal; non-NK mechanism	Que Oncology	Phase 2 complete	Randomized Phase 2 in 131 women taking tamoxifen or aromatase inhibitors, published in 2022; no Phase 3 verified	No
DARE-HRT1	Monthly intravaginal ring releasing estradiol and progesterone; hormonal	Daré Bioscience	Phase 1 and Phase 1/2 complete; pivotal program not started	Developer continues to describe later-stage development, but says additional capital is needed for unfunded programs	No FDA-approved product
DARE-VVA1	Intravaginal tamoxifen; selective estrogen receptor modulator (SERM), not estrogen	Daré Bioscience	Phase 1/2 complete; Phase 2 not started	Seventeen-woman Phase 1/2 completed; later development remains capital-dependent	No
MLE-301	NK3 antagonist; non-hormonal	Millendo Therapeutics	Discontinued	Early development was terminated after unfavorable pharmacokinetic findings	Never commercialized
SJX-653	NK3 antagonist; non-hormonal	Sojournix	Discontinued	Early development was terminated after unfavorable pharmacokinetic findings	Never commercialized

Two things we deliberately left out of that table, and why.

Supplements. PhytoSERM is being studied academically for menopausal symptoms and brain outcomes, but its registry record classifies the intervention as a dietary supplement. Mixing supplements into a drug pipeline table is exactly how these lists become misleading.

Devices and lasers. They may be studied for menopause-related symptoms, but they are not drug-development programs and do not follow an FDA drug-approval path.

Which new menopause drugs are already FDA-approved?

Three non-hormonal prescription products are FDA-approved specifically for moderate-to-severe menopausal vasomotor symptoms: Brisdelle, Veozah, and Lynkuet. Veozah and Lynkuet are the two newest and the only neurokinin-targeting products in that group. Any 2026 article still calling either one “upcoming” is out of date.

We read the current U.S. labels on September 2, 2026. Most comparisons skip the detail that will actually shape a year on treatment: what monitoring the drug requires and what interaction or warning can stop it from being the right fit.

Brisdelle is the older SSRI option and has no scheduled liver-testing program, but its tamoxifen interaction matters. Veozah carries a boxed liver-injury warning and requires six liver panels through month nine. Lynkuet requires baseline and month-three liver testing, is taken at bedtime, and added a seizure warning in August 2026.

Decision fact	Brisdelle	Veozah	Lynkuet
Active ingredient	Paroxetine mesylate 7.5 mg	Fezolinetant 45 mg	Elinzanetant 120 mg
FDA approval timing	2013	May 12, 2023	October 24, 2025
How it works	SSRI	Blocks NK3	Blocks NK1 and NK3
Hormone?	No	No	No
Usual label timing	Once daily at bedtime	Once daily	Two 60 mg capsules once daily at bedtime
Scheduled liver panels	No label-mandated schedule	Baseline, monthly for months 1–3, then months 6 and 9	Baseline and month 3
Boxed warning	Antidepressant-class suicidality warning; the label says to consider avoiding concomitant use with tamoxifen for VMS	Hepatotoxicity	None
Other practical warning	Strong CYP2D6 inhibition can reduce tamoxifen effectiveness	Stop and obtain testing if symptoms of liver injury develop	CNS/daytime impairment, photosensitivity, pregnancy risk, and risk of seizure

What that table means for your calendar. Six liver panels through month nine is a real commitment—lab appointments, results, and follow-up. Two is a different kind of year. Brisdelle avoids that particular schedule, but it brings a different decision: it should not be treated as a casual swap in a woman taking tamoxifen.

What changed in the Lynkuet label in August 2026?

The original draft said Lynkuet’s approved content still read “Revised: 10/2025” and had not changed since launch. That is no longer true. The current label says Revised: 8/2026 and lists “Risk of Seizure” as a recent major change. Postmarketing seizures have been reported, and the label tells patients with a seizure history to discuss that history with the prescriber.

The rest of the practical comparison still holds. Lynkuet’s label reports drowsiness or fatigue in 11.9% of treated women versus 3.5% on placebo. A 64-woman driving study found average performance below the prespecified impairment threshold, but three women crossed the threshold after the first dose. End-of-treatment biopsies were adequate in 477 women; no endometrial malignancies were found, and abnormal findings occurred in 0.8%.

What about women taking tamoxifen or an aromatase inhibitor?

Bayer studied elinzanetant in OASIS-4 among women receiving adjuvant endocrine therapy for hormone-receptor-positive breast cancer. The trial reported positive results, and the Lynkuet label says elinzanetant did not produce clinically significant changes in tamoxifen pharmacokinetics.

That does not turn the U.S. label into a breast-cancer-specific indication. A prescription for that purpose would still require individual oncology review, and coverage can depend on the plan. Brisdelle is a separate problem: its label warns that paroxetine can reduce tamoxifen effectiveness and says to consider avoiding concomitant use when Brisdelle is being used for vasomotor symptoms.

For the broader approved treatment landscape, see Non-Hormonal Options for Menopause Symptoms.

What do Veozah and Lynkuet cost, and will insurance pay?

The stable numbers are the manufacturer program terms, not a coupon-site snapshot that can change by pharmacy and ZIP code. Veozah and Lynkuet remain brand-only. Brisdelle and other older options may cost less, but exact pharmacy pricing varies. Insurance formularies, prior authorization, and savings-program eligibility decide the real cost.

Verified September 2, 2026: Veozah’s commercial savings program advertises $0 for the first eligible 30-day prescription and as little as $30 after that, subject to a $4,000 annual maximum. Lynkuet advertises as little as $25 with commercial insurance and a $625 program price for eligible uninsured or uncovered patients.

Cost or access question	Veozah	Lynkuet
Retail cash price	Varies by pharmacy; confirm at checkout	Official affordability program lists $625 for a 30-day supply for eligible people without insurance or without coverage
Commercial savings	As little as $0 for the first eligible prescription, then as little as $30	As little as $25 per 30-day fill
Maximum manufacturer benefit	Up to $4,000 per calendar year	Up to $2,500 per year, limited to $208.33 per 30-day fill and 12 fills
Medicare, Medicaid, TRICARE, VA, or other government insurance	Manufacturer commercial card not available	Manufacturer commercial card not available
Independent assistance	Patient-support pathways may be available based on eligibility	Independent foundation assistance may be available for some eligible publicly insured patients
Generic	No	No

Read the live terms before using either program: Veozah savings and support and the Lynkuet savings card page. The separate Lynkuet FAQ lists the $625 affordability-program price for eligible patients without insurance or without coverage. Program rules can change before this article’s next scheduled review.

The comparison nobody puts next to those numbers: older generics used for hot flashes can cost much less than a new brand drug, but “cheaper” and “right for you” are not the same decision. Brisdelle’s tamoxifen interaction is one reason the lowest pharmacy price cannot be the only filter.

If you have Medicare Part D, the 2026 annual out-of-pocket threshold is $2,100 for covered Part D drugs. After you reach it, you owe no cost sharing for covered Part D drugs for the rest of the year. An uncovered drug or a purchase outside the plan does not automatically count toward that threshold.

Three questions to ask before you fill either new brand drug:

Is it on my plan’s formulary, and what tier?
Does it require prior authorization, and who submits it?
Am I eligible for the manufacturer program, or does my insurance type disqualify me?

Knowing those three answers before you pay is worth more than any coupon headline.

Is Fylrevy approved in the United States?

No. Estetrol, developed as Donesta and approved in Europe as Fylrevy, received its European Union marketing authorization on March 26, 2026 for estrogen-deficiency symptoms in postmenopausal women. It is a hormone therapy. It is not FDA-approved, and we found no public confirmation of a U.S. submission or accepted application by September 2, 2026.

This is the clearest illustration on the page of why pipeline coverage goes stale—and it is worth two minutes.

The timeline, dated:

2022–2023: Mithra reported Phase 3 results from E4COMFORT I and II, which together enrolled 2,576 postmenopausal women.
November 30, 2023: Mithra said FDA guidance required additional analyses of endometrial-biopsy data because pathologists varied in how some samples were classified. At that time, the company moved its planned U.S. filing to the fourth quarter of 2024.
June 11, 2024: Gedeon Richter completed the acquisition of the estetrol platform from Mithra’s insolvency process; the transaction was announced June 12.
January 29, 2026: The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion.
March 26, 2026: The European Commission granted marketing authorization. Richter announced it March 27 as Fylrevy, with 14.2 mg and 18.9 mg tablets.
August 7, 2026: Richter reported that Fylrevy had launched in selected pilot markets in Europe.
September 2, 2026: No public FDA submission, acceptance, review date, or U.S. launch was found.

The detail that connects the record without pretending it proves causation. The 2023 U.S. delay involved endometrial-biopsy interpretation. The European product information lists uterine-lining findings—including endometrial thickening and vaginal bleeding—among common effects in women with a uterus taking the required progestogen regimen. Both records involve endometrial assessment. The public documents do not establish that one caused the other.

What this means for you: European approval is not American access. Fylrevy is not available as an FDA-approved U.S. prescription product, and it has no public U.S. timetable. If you were holding out for “the new natural estrogen,” you were holding out for a drug with no published American date.

Which non-hormonal menopause drugs are actually in trials now?

Five non-hormonal candidates remain active enough to track: ABCL635, asimadoline, cendifensine, refisolone, and GS1-144. Their evidence is not equal. One has a company-reported placebo-controlled four-week result, one has no efficacy result, one was open-label, one rests on a 36-woman exploratory study, and one completed Phase 2 in China.

ABCL635 — the shot

The punchline: the freshest placebo-controlled result of 2026, and still only four weeks long, from 92 women, reported by the company.

AbCellera is developing an antibody that blocks NK3—the same receptor targeted by Veozah, with a completely different delivery model. It is a subcutaneous injection designed to last longer than a daily pill.

On August 10, 2026, the company reported the Phase 2 portion of its Phase 1/2 trial: 92 postmenopausal women, 46 on ABCL635 and 46 on placebo, averaging about 10 moderate-to-severe hot flashes per day at baseline. Each participant received one 600 mg injection.

Hot flash frequency fell by 8.8 events per day versus 3.5 with placebo: a placebo-adjusted difference of 5.3 (p<0.001).
Mean percentage reduction was 83% versus 33%.
Severity fell 58% versus 12%.
The company reported sleep improvement, no serious or severe treatment-emergent adverse events during the four-week window, and headache, fatigue, and injection-site reactions among events occurring more often than with placebo.

Trial investigator JoAnn Pinkerton, MD, called the four-week result “a new efficacy benchmark” in AbCellera’s announcement. She was involved in the trial. The data are sponsor-reported and not yet a peer-reviewed Phase 3 package.

What it does not establish: how long the effect lasts, the final dosing schedule, long-term safety, Phase 3 success, FDA acceptance, approval, price, or a launch date. The registered study continues beyond the four-week readout. Phase 3 has not started.

Asimadoline (TP0052) — the different target

The punchline: a genuinely different mechanism, a registered Phase 2a design, and zero published efficacy data.

Tioga Pharmaceuticals is testing asimadoline, a peripherally acting kappa-opioid receptor agonist. The protocol for NCT07042516 is randomized, double-blind, and placebo-controlled, followed by an open-label period. The public record targeted 120 women.

Recruitment text has not been consistently current across public copies of the registry record, so this page does not promise that a site is enrolling. Check the live ClinicalTrials.gov record before contacting Emory or making travel plans.

Interesting mechanism, real trial design, no result. Anyone telling you it works is telling you about a hypothesis.

Cendifensine (NOE-115) — the big number with the big asterisk

The punchline: a 92.3% reduction sounds extraordinary. It came from an open-label study with no placebo group, so the drug effect cannot be separated from symptom fluctuation, observation, expectation, or regression to the mean.

Noema Pharma’s candidate inhibits reuptake of serotonin, norepinephrine, and dopamine. The Phase 2a program enrolled 40 women across three sequential cohorts; 35 were in the two 12-week cohorts highlighted in the sponsor’s topline report, and 18 received the 30 mg dose tied to the headline number.

At 30 mg, the sponsor reported a 92.3% reduction in hot flash frequency and a 59.2% reduction in severity. The 60 mg cohort did not produce a larger effect. Mood, fatigue, cravings, and weight were exploratory outcomes. Reported common adverse events included dry mouth, headache, constipation, and insomnia.

Noema has said it intends to move into Phase 2b. That is the right next study, and it is the study that would begin answering the placebo question. We did not verify a registered Phase 2b by September 2, 2026.

Refisolone (PH80) — the nasal spray

The punchline: the most different delivery idea in the group, on the thinnest placebo-controlled dataset, with a regulatory milestone that is easy to misread.

Vistagen is developing a microgram-dose intranasal spray intended for use as needed. The company describes it as acting through nasal neurocircuitry without systemic absorption. That is a proposed product profile, not an FDA finding.

The menopause evidence is an exploratory, randomized, double-blind, placebo-controlled Phase 2a study conducted in Mexico in 36 women. The company reported an 80% frequency reduction with refisolone versus 36% with placebo over four weeks.

On April 22, 2026, Vistagen announced that the FDA had issued a “Study May Proceed” letter under its U.S. IND. Read that carefully: it means the FDA did not block the proposed study from proceeding. It is not approval, product clearance, or a judgment that the nasal spray works.

GS1-144 — the one that finished

The punchline: the largest completed investigational dataset on this list—276 women, randomized and placebo-controlled, with a peer-reviewed 2026 publication—and no U.S. path we could verify.

GenSci developed GS1-144 as another oral NK3 antagonist. The 12-week Phase 2 study in China enrolled 276 women and reported reductions in moderate-to-severe vasomotor symptoms. Bigger and more developed than most of this list does not mean available in America. We found no registered U.S. program or public U.S. filing plan.

How should you read a menopause drug headline?

Efficacy percentages from different trials are not interchangeable. A placebo-controlled study reports both the drug-group change and the placebo-group change; the gap matters. An open-label study reports only what happened after everyone knew they received the drug. Sample size, duration, source, and placebo design decide how much weight a headline deserves.

The table below is an evidence-design comparison, not a ranking of drugs. ABCL635 and refisolone have placebo groups but short, sponsor-reported datasets. Cendifensine has no placebo arm. Lynkuet and Veozah have FDA-reviewed programs. The numbers answer different questions and should not be lined up as if the largest percentage “wins.”

Drug	Headline number	Design and denominator	What placebo did	What can actually be concluded
ABCL635	83% mean frequency reduction	Randomized, double-blind, placebo-controlled; 92 women; four-week readout	33% mean reduction	50-percentage-point difference at week 4 after one injection; sponsor-reported, not long-term
Cendifensine	92.3% mean frequency reduction at 30 mg	Open-label; 18 women at the headline dose; no placebo	No placebo group	Placebo-adjusted effect cannot be calculated
Refisolone	80% frequency reduction	Exploratory randomized, double-blind, placebo-controlled; 36 women; four weeks	36% reduction	About a 44-percentage-point difference; small, company-reported study
Lynkuet	Large reduction across pivotal trials	Randomized, double-blind, placebo-controlled Phase 3 program plus long-term safety study	Placebo also improved substantially	FDA concluded the total package supported approval for moderate-to-severe VMS
Veozah	Significant reductions at weeks 4 and 12	Two randomized, double-blind, placebo-controlled Phase 3 efficacy trials plus safety data	Placebo improved	FDA concluded the total package supported approval; postmarketing liver injury later changed the label

Look at the open-label row. That study measured the drug plus everything else that happens when symptoms fluctuate and participants know they are being treated. The problem is not that early science exists. The problem is a headline that drops the qualifier.

Carry these four questions to every menopause drug headline:

Was there a placebo group, and what did it do?
How many women contributed to the headline number?
How long were they followed?
Whose number is it—an FDA label, peer-reviewed paper, registry result, conference abstract, or sponsor release?

That four-question audit is the moat here. It turns “92%” from a promise into a study design.

Why doesn't a positive Phase 2 result mean approval next year?

A positive Phase 2 result still leaves larger confirmatory trials, longer safety follow-up, manufacturing work, an FDA application, and agency review. None of the investigational candidates on this page has a confirmed U.S. application. “2030 or later” is an editorial earliest-case estimate for today’s Phase 2 programs—not company guidance and not a promise.

Compare the two ends of the evidence chain.

ABCL635’s August 2026 result: 92 women, one dose, four weeks of reported efficacy.

Lynkuet’s approval package: 1,420 women across three trials, including a 52-week safety study, 477 evaluable endometrial biopsies, a driving study, nonclinical work, manufacturing controls, and an FDA review.

That gap is the pipeline. It is measured in years, participants, manufacturing validation, and unanswered safety questions.

Two old NK3 names show where that gap can end: MLE-301 and SJX-653. Both entered early human development. Both were later discontinued after unfavorable pharmacokinetic findings. They did not fail because a headline was insufficiently enthusiastic. They stopped because the drug did not behave well enough in the body to keep moving.

The stale-record problem is different. HS-10384 still has a Phase 2 registry entry but no result or current milestone we could verify. Q-122 has a published randomized Phase 2 result but no Phase 3 we could verify. Neither belongs in “active and close,” and neither should be declared dead without evidence.

The line to take away: a pipeline is a queue of maybes. Treating it as a schedule is the most expensive thing a woman with disruptive symptoms can do with her own time.

If you have been putting off treatment until “the new one” arrives, you have now seen the timelines. The next step is not picking a drug from a pipeline chart. It is finding out which treatment lane fits your symptoms, history, insurance, state, and medication preference. Use Find My HRT Path to get that answer in about 90 seconds →

What's coming for vaginal dryness, painful sex, and urinary symptoms?

Almost nothing new is close. Dryness and painful sex already have FDA-approved treatment options. Recurrent urinary tract infection prevention is a separate claim: vaginal estrogen is guideline-recommended for many peri- and postmenopausal women with recurrent UTIs, but the local products are not FDA-approved specifically as UTI-prevention drugs.

Here is the story worth understanding, because it is a live example of the single most important regulatory distinction in menopause care.

Daré Bioscience developed DARE-HRT1, a monthly intravaginal ring designed to release estradiol and progesterone. Phase 1 and Phase 1/2 studies are complete. The company continues to describe an FDA-development path, but its 2026 filings say additional capital is needed for programs not backed by grant or other funding. No pivotal Phase 3 trial was verified.

Daré is also pursuing a commercial compounding route. DARE to RECLAIM is the planned brand for a related estradiol-progesterone intravaginal ring produced through a Section 503B outsourcing facility. The company’s 2025 annual filing targets prescription fulfillment in early 2027 on a cash-pay basis.

Related formulation. Two completely different regulatory realities.

Compounded drugs are not FDA-approved. FDA does not evaluate a compounded drug for safety, effectiveness, or quality before it is marketed. A Section 503B outsourcing facility must register, follow applicable current good manufacturing practice requirements, and is subject to FDA inspection—but facility registration is not approval of the finished compounded product.

A compounded product is not automatically safer, more natural, or medically interchangeable with an FDA-approved finished drug. “Bioidentical” is not an FDA approval category.

There are legitimate clinical reasons a prescriber may order a compounded drug, including a needed dosage form or ingredient combination that is not commercially available for a particular patient. “It sounds newer and more natural” is not a regulatory reason.

Daré’s other genitourinary candidate, DARE-VVA1, delivers tamoxifen intravaginally for moderate-to-severe dyspareunia associated with vulvar and vaginal atrophy. A 17-woman Phase 1/2 study was completed. Later development remains funding-dependent.

What you can get now: FDA-approved options for specific GSM/VVA indications include low-dose vaginal estrogen products, vaginal prasterone for moderate-to-severe dyspareunia, and oral ospemifene for moderate-to-severe dyspareunia and vaginal dryness. For recurrent UTIs, the treatment decision should be framed against the current urology guideline rather than pretending the vaginal-estrogen label itself says “UTI prevention.”

If dryness, painful sex, urinary urgency, or recurrent UTIs are your main problem, start with the practical guide to vaginal estrogen instead of waiting for DARE-HRT1.

Is anything coming for sleep, mood, joint pain, bone loss, or low libido?

Not as a near-term standalone menopause-drug wave. The active investigational programs here are built primarily around hot flashes and night sweats. Sleep, mood, fatigue, or weight may appear as secondary or exploratory outcomes, but that does not create a separate FDA indication for insomnia, depression, brain fog, joint pain, or libido.

We know this is the least satisfying section on the page. It is also the most honest one, and it changes what you should do.

Sleep: Lynkuet and ABCL635 studies measured sleep outcomes. That can matter to a woman whose sleep is being broken by hot flashes, but it is not the same as approval for a primary sleep disorder.
Mood, fatigue, cravings, and weight: cendifensine tracked these as exploratory outcomes. Exploratory means interesting, not established.
Joint and muscle pain or brain fog: no dedicated approval program in this tracker.
Bone: approved hormone and non-hormone treatments already exist for appropriate patients; that is not a reason to wait for a hot-flash candidate.
Low libido: there is still no FDA-approved testosterone product indicated for women in the United States. Testosterone is a Schedule III controlled substance and always requires a prescription and clinician evaluation. The evidence-based use discussed in international guidance is carefully monitored, off-label systemic treatment for selected postmenopausal women diagnosed with hypoactive sexual desire disorder—not general energy, mood, weight loss, or “optimization.”

The practical read: if hot flashes are your main problem, this pipeline is relevant. If your main problem is something else on this list, waiting for a new hot-flash drug means waiting for a drug that is not being built for your actual problem.

For the fuller low-desire decision, see Libido and Sexual Health in Menopause.

Can any drug delay menopause itself?

No drug is FDA-approved to delay natural menopause or ovarian aging. The best-known human effort is VIBRANT, a small Columbia University study of weekly low-dose rapamycin in women approaching menopause. It is an investigator-led pilot, not an approved indication, not a fertility guarantee, and not a reason to self-prescribe an immunosuppressant.

This is a genuinely interesting research field being reported far ahead of its evidence.

Rapamycin is already approved for other medical uses and has significant risks and monitoring requirements. The VIBRANT protocol is testing whether a low weekly dose changes markers of ovarian aging. A small pilot cannot establish delayed menopause, longer fertility, long-term safety, or a commercial approval path.

Anti-Müllerian hormone approaches are being explored in preclinical work as another way to slow follicle activation. Preclinical means before the evidence needed to tell a woman that a product will delay her menopause.

Two boundaries, stated plainly:

Delaying menopause and treating menopause symptoms are different fields. Only symptom treatment has FDA-approved menopause drugs today.
Taking rapamycin for ovarian aging outside a legitimate clinical study is not supported by evidence. We are not going to tell you how to get it for this purpose.

Should you join a menopause clinical trial?

A legitimate clinical trial can give you access to an investigational drug before approval, but access is not treatment certainty. You may receive placebo, eligibility rules can be narrow, visits and testing may be demanding, and continued access after the trial may not exist. Recruitment status can change faster than an article can update.

Search ClinicalTrials.gov by condition and location, then open the live record—not a copied trial listing. Programs on this page with U.S. registry records include ABCL635 (NCT07118891) and asimadoline (NCT07042516), but a registered study is not automatically recruiting near you.

Before you sign anything, ask these five questions:

Could I be randomized to placebo, and for how long?
Is there an extension in which everyone receives the investigational drug?
Who pays for the study drug, tests, travel, and treatment of a study-related injury?
What visits, diaries, blood tests, biopsies, or procedures are required?
Who do I contact after hours if something goes wrong?

One thing to expect: hot-flash trials usually require a high symptom count and daily electronic diaries. Lynkuet’s pivotal trials required at least 50 moderate-to-severe vasomotor symptoms per week. A woman with four hot flashes a day may not qualify.

A trial’s purpose is research. It may help you. It is not guaranteed treatment, and it is not a substitute for a care plan while you wait.

Should you wait for a new menopause drug or start now?

For most women with disruptive symptoms, waiting solely for the investigational pipeline is the wrong plan. No active candidate here has a confirmed U.S. application or launch date. Three non-hormonal prescriptions and the established hormone-therapy toolkit already exist. The right next step depends on your symptom, risk profile, and treatment preference—not a biotech headline.

Find the row that matches your actual problem. Hot flashes already have hormone and non-hormone prescription options. Vaginal symptoms already have local treatments. The investigational pipeline is not building a near-term answer for every sleep, cognition, joint, or libido complaint. “Watch and wait” only makes sense when your symptoms are manageable and you choose it knowingly.

If this is you	The honest answer
Hot flashes, and you can use systemic estrogen	Hormone therapy remains the most effective treatment for vasomotor symptoms for appropriate candidates. Start the clinical conversation rather than waiting for Phase 2.
Hot flashes, and you cannot or do not want to use estrogen	Brisdelle, Veozah, and Lynkuet are FDA-approved now. The choice turns on interactions, liver monitoring, seizure history, daytime impairment, pregnancy potential, and coverage.
Taking tamoxifen or an aromatase inhibitor	Do not treat all non-hormonal options as interchangeable. Brisdelle can interfere with tamoxifen; OASIS-4 studied elinzanetant, but the U.S. label is not breast-cancer-specific. Involve the oncology team.
Vaginal dryness, painful sex, urinary urgency, or recurrent UTIs	The pipeline is thin because approved or guideline-supported options already exist. Use a GSM-specific appointment, not a hot-flash waitlist.
Sleep, mood, joint pain, or brain fog is your worst symptom	No candidate here is seeking approval specifically for that problem. Identify the driver and treat what can be treated now.
Bothered but managing, and simply curious	Watching is reasonable. Bookmark this page and re-check the dated status instead of making a treatment decision from a press release.

A small next step, if a big one feels like too much: you do not have to book anything today. You do have to know which row you are in. That is a 90-second routing decision, not a prescription decision.

Who can prescribe and monitor Veozah or Lynkuet online?

Both drugs require baseline liver bloodwork and follow-up testing, and both may require prior authorization because they are brand-only. The right care model must be able to order or review hepatic labs, act on abnormal results, confirm the specific drug is within the clinician’s scope, and support an insurance authorization. A visit never guarantees a prescription.

Affiliate disclosure: The HRT Index has active affiliate relationships with some providers named on this site, including Midi Health, Sesame, Winona, Hers, and Inner Balance. That does not turn a provider visit into a prescription guarantee. Our provider assessments use The HRT Index Verification Standard and never publish an invented per-provider numeric score. Full disclosure.

The best route depends on how you pay and what you need the clinician to manage. Midi is the clearest insurance-first model in this group. Sesame can offer visible visit or program pricing, but clinician services vary. Winona and Inner Balance are not the natural first route for a brand-only neurokinin drug that needs liver monitoring and prior authorization.

Care path	Provider-stated public facts — checked September 2, 2026	Best fit here	Confirm before booking
Midi Health	Available in all 50 states; in-network with most PPO plans; self-pay pricing is $250 for an initial visit and $150 for follow-up	Insurance-first menopause care with scheduled clinician visits	Whether your exact plan is in-network; whether the clinician prescribes the requested drug; where hepatic labs are ordered; who handles prior authorization
Sesame Care	Menopause subscription is listed from $59/month; medication costs are separate; Sesame does not bill health insurance; CBC, A1c, thyroid, lipid panel, and CMP are included if the provider orders them, with state-specific lab-payment exceptions	Cash-pay reader who values a visible care price before booking	Whether the selected clinician is licensed in your state and manages the specific drug, follow-up, and prior authorization; whether your lab location triggers a direct lab charge
Winona	Does not bill insurance directly; published examples include an $89/month estrogen body cream and a $149/month FDA-approved estradiol patch, kept separate from its compounded products	Broader cash-pay HRT discussion, not the default brand-drug/PA route	State eligibility, exact finished product, pharmacy, lab plan, and whether the requested non-hormonal brand is offered
Inner Balance / Oestra	Oestra is compounded and cash-pay; the published price is $199/month for the first six months, then $99.50/month; the finished product is not FDA-approved	A reader specifically seeking that compounded model after understanding the trade-off	State eligibility, why a compounded product is clinically needed, whether dose adjustments add cost, and how monitoring and endometrial protection are handled

We are naming Winona and Inner Balance and then telling you they are the wrong shape for this specific decision. A compounded or cash-pay HRT model can be a fit for a different reader. It is not the obvious route for a brand-only neurokinin drug that may need formulary review, liver panels, and a prior authorization. Pretending otherwise would make this page worse.

One policy worth knowing before the cheaper-looking Sesame route wins on price: Sesame says cancellation at least three hours before the initial visit is refundable. Once the initial visit has occurred, the first month is nonrefundable; future charges stop only when you cancel before the next billing cycle. That is clear—but it means “$59 to try it” is not the same as a no-risk trial after the visit starts.

Here is the damaging admission on the insurance-first pick. Midi does not publish one tidy all-in monthly number. An appointment is an evaluation, not a guarantee that a clinician will prescribe Veozah, Lynkuet, or anything else. If a knowable cash price before booking matters more than insurance billing, Sesame may be the cleaner first comparison. But if your PPO covers Midi, the messy insurance route can be the more useful route precisely because it can connect the visit, pharmacy benefit, laboratory work, and prior authorization.

Ready to use what is approved instead of waiting on what is not? Compare the current insurance-first and cash-pay provider routes →

Still unsure which route fits your situation? Use Find My HRT Path before you book →

What did The HRT Index verify—and what could not be verified?

Read in full or checked against current primary records on September 2, 2026:

Current FDA-approved prescribing information for Brisdelle, Veozah, and Lynkuet.
Lynkuet’s August 2026 revision, including the new seizure warning, liver-testing schedule, daytime impairment data, driving study, endometrial biopsies, and tamoxifen pharmacokinetics.
Veozah’s boxed hepatotoxicity warning and six-test monitoring schedule.
Current manufacturer savings-program terms and the 2026 Medicare Part D out-of-pocket threshold.

Confirmed from regulators, registries, peer-reviewed papers, company filings, or dated sponsor reports:

ABCL635’s August 10, 2026 placebo-controlled topline result and NCT07118891.
Asimadoline’s NCT07042516 protocol, with recruitment to be checked on the live record.
Cendifensine’s open-label design, cohort sizes, and sponsor-reported result.
Refisolone’s April 22, 2026 “Study May Proceed” letter and 36-woman exploratory result.
GS1-144’s 276-woman peer-reviewed Phase 2 study.
Fylrevy’s March 26, 2026 European authorization and its lack of verified U.S. approval.
Daré’s separate FDA-development and Section 503B compounding paths.
Q-122’s published Phase 2 result and the lack of a verified Phase 3.
The discontinuation of MLE-301 and SJX-653.

What we could not verify—and will not guess:

A U.S. submission, accepted application, review date, or launch for Fylrevy/Donesta.
A Phase 3 program for Q-122.
A formally registered Phase 2b study for cendifensine.
A current result or reliable development status for HS-10384.
A future retail price for any investigational drug.
A guaranteed prescription or prior-authorization outcome from any telehealth provider.

What this page is not: medical advice, a prediction market, or a clinician review. It is dated editorial research with the evidence source identified. We also do not publish patient testimonials as proof that a drug works. One woman’s experience cannot convert an investigational result into evidence.

How did we build this menopause drug pipeline tracker?

We used The HRT Index Verification Standard: clinical legitimacy, care quality, medication fit, price transparency, access. For this research page, that means separating regulator decisions from sponsor language, FDA-approved products from compounded products, placebo-controlled evidence from open-label evidence, and current access from future intent.

What earns a row: a named prescription drug or drug-development program studied in humans for a menopause symptom or a defined menopause population, with a status traceable to an FDA or EMA record, trial registry, peer-reviewed paper, conference result, company filing, or dated sponsor release.

What does not: a supplement without a drug-approval path, a device, a laser, a preclinical concept, a market-report mention, or an approved drug misleadingly relabeled as “pipeline” for the use already on its label.

What we refuse to publish: approval-probability percentages, “most likely to be approved” rankings, invented launch dates, cross-trial efficacy rankings, or “breakthrough” unless it is a formal FDA designation we can cite.

That is why the original evidence asset on this page is not a prediction. It is the status-plus-placebo ledger: access, stage, denominator, placebo design, evidence source, last milestone, and the unanswered question on the same line.

Frequently asked questions

What is the newest FDA-approved menopause drug?

Lynkuet (elinzanetant) is the newest FDA-approved prescription drug specifically for moderate-to-severe vasomotor symptoms due to menopause, approved October 24, 2025. It is a non-hormonal NK1/NK3 antagonist. Its label was revised in August 2026 to add a seizure warning.

How many non-hormonal drugs are FDA-approved for menopausal hot flashes?

Three branded prescription products are FDA-approved specifically for moderate-to-severe vasomotor symptoms associated with menopause: Brisdelle, Veozah, and Lynkuet. Veozah and Lynkuet are the two newer neurokinin-targeting drugs.

What's the difference between Brisdelle, Veozah, and Lynkuet?

Brisdelle is low-dose paroxetine and has an important tamoxifen interaction. Veozah blocks NK3, carries a boxed hepatotoxicity warning, and requires six liver panels through month nine. Lynkuet blocks NK1 and NK3, is taken at bedtime, requires baseline and month-three liver tests, and carries warnings for daytime impairment, pregnancy risk, photosensitivity, and seizure risk.

When will the next new menopause drug be approved?

No investigational candidate in this tracker has a confirmed U.S. marketing application or review date as of September 2, 2026. Today’s Phase 2 programs would still need later-stage evidence, an application, and FDA review. “2030 or later” is an earliest-case editorial estimate, not company guidance.

Why does Veozah have a boxed warning and Lynkuet does not?

FDA added Veozah’s boxed warning after a postmarketing report of serious liver injury and strengthened its testing schedule. Lynkuet does not have a boxed warning, but its label still requires liver testing and now includes a seizure warning added in August 2026.

Do Veozah and Lynkuet require blood tests?

Yes. Both require baseline liver testing. Veozah requires repeat testing monthly for the first three months and again at months six and nine. Lynkuet requires repeat testing at month three. Neither should be started when specified liver enzymes or bilirubin are at least twice the upper limit of normal.

How much do Veozah and Lynkuet cost without insurance?

Pharmacy cash prices vary. Lynkuet’s official affordability program lists $625 for a 30-day supply for eligible people without insurance or without coverage. Veozah does not publish one universal cash price on its savings page. Commercially insured patients may qualify for manufacturer savings, subject to the live terms.

Can a woman taking tamoxifen use a non-hormonal menopause drug?

That is not a one-drug-fits-all decision. Brisdelle’s label warns that paroxetine can reduce tamoxifen effectiveness. Elinzanetant was studied in OASIS-4 among women taking tamoxifen or aromatase inhibitors, but the U.S. label is not a breast-cancer-specific indication. The oncology team should be part of the decision.

Is Fylrevy available in the United States?

Not as an FDA-approved product. Fylrevy received European Union marketing authorization in March 2026. We found no public confirmation of a U.S. submission, accepted application, review, or launch by September 2, 2026.

Is there a pill that can delay menopause?

No drug is FDA-approved to delay natural menopause or ovarian aging. Rapamycin is being studied in a small investigator-led trial, but it is not approved for this purpose and should not be self-prescribed for ovarian aging.

Is there an FDA-approved testosterone product for women?

No testosterone product is FDA-approved with an indication for women in the United States. Testosterone is a Schedule III controlled substance and requires a prescription and clinician evaluation. Evidence-based guidance limits the supported off-label discussion to carefully selected postmenopausal women diagnosed with hypoactive sexual desire disorder.

Should I wait for a new drug or start treatment now?

If symptoms are disruptive, do not wait solely because a Phase 2 headline sounds close. Approved hormone and non-hormone options already exist, while no investigational candidate here has a confirmed U.S. filing date. Use your symptom, medical history, risk profile, and coverage to decide the next clinical conversation.

Sources and evidence records

Every source above was accessed or re-checked on September 2, 2026.

Update schedule

This page tracks a moving target. Last verified September 2026.

FDA labels and manufacturer access terms: re-check monthly.
Trial status, results, filings, approvals, and discontinuations: re-check quarterly and after any material announcement.
Provider insurance, pricing, laboratory, and medication claims: re-check before each provider CTA refresh.
Corrections: document the changed claim, the source, and the correction date on the site’s corrections page.

Found something we got wrong or missed? Send the primary source. We would rather correct a dated ledger than defend a stale sentence.

Still not sure which HRT program is right for you? Take our free, about-90-second Find My HRT Path quiz.

Choose the care route that matches what is available now.

Compare nonhormonal menopause options, review the current menopause medication list, or use Find My HRT Path to identify your next step.

Keep reading: